The biology and treatment of chronic myelogenous leukemia

ONCOLOGY

Volumn 15, Issue 1, 2001, Pages 23-30

  Brunstein, Claudio G ^a   Mcglave, Philip B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CYTARABINE; HYDROXYUREA; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; REVIEW; SURVIVAL;

ANTINEOPLASTIC AGENTS; BUSULFAN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTARABINE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS;

EID: 0035219890     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Verfaillie CM: Biology of chronic myelogenous leukemia. Hematol Oncol Clin North Am 12:1-29, 1998.
2. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 340:1330-1340, 1999.
3. Sokal JE, Cox EB, Baccarani M, et al: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799, 1984.
4. Faderl S, Talpaz M, Estrov Z, et al: The biology of chronic myeloid leukemia. N Engl J Med 341:164-172, 1999.